 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | pomalidomide / Generic mfg.
Retrospective data, Journal: BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma. (Pubmed Central) - Nov 30, 2024
Our results confirmed that BCMA CAR T-cell therapy combined with long-term pomalidomide had a low recurrence rate and manageable therapy-related side effects, providing a promising option for treating R/R MM.
- ssCART-19 / Shanghai Unicar, U51 / Shanghai Unicar
5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_5460;
Our preliminary study showed that anti-CD19 and anti-BCMA CAR-T cell therapy followed by lenalidomide maintenance after ASCT yielded encouraging activity for high-risk NDMM...Conclusions : To the best of our knowledge, this is the first clinical trial to incorporate anti-BCMA and anti-CD19 CAR-T cells as consolidation therapy for high-risk NDMM patients...This novel therapeutic strategy shows promise in addressing the unmet needs of high-risk NDMM patients, potentially offering a new direction in the management of this challenging subgroup of multiple myeloma. Further studies are warranted to confirm these encouraging results and to fully elucidate the role of dual-target CAR-T cell therapy in the treatment paradigm for high-risk NDMM.
- U51 / Shanghai Unicar
Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_5444;
The BiRD regimen (clarithromycin, lenalidomide and dexamethasone) was evaluated for NDMM (newly diagnosed MM) patients in 2008, which demonstrated good efficacy and tolerance without neurotoxicity...Moreover, an improvement of most QoL domains of the QLQ-C30 and QLQ-MY20 was observed from baseline to the period after BCMA CAR T cell, especially pain and disease symptom. Conclusion This study firstly demonstrates that BiRD regimen followed by anti-BCMA CAR T-cell therapy can induce deep and early remission for NDMM patients with good tolerance even for high risk patients, providing a novel front-line treatment option for NDMM.
- | BCMA CAR T-cell therapy / Shanghai Unicar
Journal, CAR T-Cell Therapy: Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. (Pubmed Central) - Apr 8, 2022
P1/2
Although the sample size was small and there was a lack of control in this single-arm study, the clinical benefits observed warrant ongoing randomized controlled trials. This trial was registered at ClinicalTrials.gov (NCT03455972).
- U51 / Shanghai Unicar
New P2 trial, CAR T-Cell Therapy: Anti-BCMA CAR T-Cell Therapy for R/R ITP (clinicaltrials.gov) - Apr 6, 2022
P2, N=5, Recruiting, Sponsor: The First Affiliated Hospital of Soochow University
- | BCMA CAR T-cell therapy / Shanghai Unicar
Journal, CAR T-Cell Therapy: Immunoglobulin Isotype Switch after Anti-BCMA CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma. (Pubmed Central) - Mar 11, 2022
This trial was registered at ClinicalTrials.gov (NCT03455972). No abstract available
- ||||| U51 / Shanghai Unicar
Enrollment change, CAR T-Cell Therapy: Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - Oct 24, 2021
P3, N=20, Recruiting, Sponsor: The First Affiliated Hospital of Soochow University
No abstract available N=30 --> 20
- | U51 / Shanghai Unicar
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - Aug 18, 2021
P3, N=30, Recruiting, Sponsor: The First Affiliated Hospital of Soochow University
N=30 --> 20 Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2022 --> Jan 2023
- |||| U51 / Shanghai Unicar
New P3 trial, CAR T-Cell Therapy: Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - Feb 27, 2020
P3, N=30, Recruiting, Sponsor: The First Affiliated Hospital of Soochow University